Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.32 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4765238 | 1.00 | POLRMT (0.35) | POLRMTMAP4K4DOT1LTNIK | |
| SCHEMBL10101549 | 0.90 | POLRMT (0.36) | POLRMTMAP4K4DOT1LTNIK | |
| SCHEMBL10101489 | 0.90 | POLRMT (0.36) | POLRMTMAP4K4DOT1LTNIK | |
| SCHEMBL15257392 | 0.81 | ADK (0.30) | — | |
| SCHEMBL17131346 | 0.81 | POLRMT (0.41) | POLRMTMAP4K4DOT1L | |
| SCHEMBL4765542 | 0.81 | — | — | |
| SCHEMBL4765508 | 0.81 | — | — | |
| SCHEMBL16479516 | 0.79 | POLRMT (0.40) | POLRMTDOT1L | |
| SCHEMBL806951 | 0.79 | POLRMT (0.40) | POLRMTDOT1L | |
| SCHEMBL19101901 | 0.79 | POLRMT (0.40) | POLRMTDOT1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226140-A1 | 2' FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-08-10 | — | — | US | disclosed |
| US-20140200188-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2014-07-17 | — | — | US | disclosed |
| US-20120107274-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200188-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, NSUN2, SLC29A2 | POLRMT 101/4885MAP4K4 1279/4885DOT1L 1296/4885 |
| US-20170226140-A1 | 2' FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, NUDT1, NSUN2 | POLRMT 103/4885MAP4K4 1486/4885DOT1L 1221/4885 |
| US-20120107274-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, NUDT1, SLC29A2 | POLRMT 103/4885MAP4K4 1289/4885DOT1L 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.